Published in Bone Marrow Transplant on August 01, 2003
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood (2009) 1.70
Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol (2013) 1.15
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant (2007) 1.02
Treatment-related myelodysplasia in patients with primary brain tumors. Neuro Oncol (2012) 0.89
Therapy-related myeloid neoplasms - what have we learned so far? World J Stem Cells (2016) 0.87
Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev (2011) 0.87
Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2016) 0.85
Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. Cancer (2014) 0.85
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant (2016) 0.79
Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients. Cancer Biol Ther (2013) 0.78
Role of hematopoietic stem cell transplant in the management of follicular lymphoma. Oncologist (2009) 0.76
Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytes. PLoS One (2017) 0.75
Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care. Biol Blood Marrow Transplant (2016) 0.75
Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol (1995) 5.51
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia (2007) 3.95
Acquired C1 esterase inhibitor deficiency. Ann Intern Med (2000) 3.27
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia (2009) 3.23
Mutations and prognosis in primary myelofibrosis. Leukemia (2013) 3.13
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia (2008) 3.04
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood (1992) 2.81
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med (1997) 2.66
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res (2006) 2.41
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia (2008) 2.35
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia (2013) 2.25
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Current concepts in anticoagulant therapy. Mayo Clin Proc (1995) 2.21
Acute megakaryocytic leukemia (M7) in children. Mayo Clin Proc (1989) 2.13
Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol (1994) 2.13
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia (2013) 2.11
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol (2001) 2.10
Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med (1990) 2.05
Paroxysmal nocturnal hemoglobinuria as a marker for clonal myelopathy. Am J Med (1992) 2.04
Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 2.02
Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med (1996) 1.99
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia (2006) 1.95
Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer (2000) 1.95
Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med (2000) 1.94
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia (2011) 1.92
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Am J Hematol (1998) 1.85
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res (2000) 1.81
Long-term use of anagrelide in young patients with essential thrombocythemia. Blood (2001) 1.81
True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood (1995) 1.81
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia (2010) 1.81
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia (2007) 1.79
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia (2011) 1.79
Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia (2010) 1.79
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta (2001) 1.78
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol (2005) 1.75
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood (2001) 1.74
Cytogenetic analysis of six renal oncocytomas and a chromophobe cell renal carcinoma. Evidence that -Y, -1 may be a characteristic anomaly in renal oncocytomas. Cancer Genet Cytogenet (1992) 1.73
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia (2010) 1.72
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia (2006) 1.71
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia (2013) 1.69
Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol (1985) 1.67
Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant (2001) 1.67
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood (1985) 1.67
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther (2007) 1.67
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood (1996) 1.65
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia (2010) 1.64
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia (2010) 1.63